EphA8 inhibits cell apoptosis via AKT signaling and is associated with poor prognosis in breast cancer

Wang,Gui-Hua; Ni,Kan; Gu,Changjiang; Huang,Jianfei; Chen,Jing; Wang,Xu-Dong; Ni,Qichao

doi:10.3892/or.2021.8134

EphA8 inhibits cell apoptosis via AKT signaling and is associated with poor prognosis in breast cancer

Authors:
- Gui-Hua Wang
- Kan Ni
- Changjiang Gu
- Jianfei Huang
- Jing Chen
- Xu-Dong Wang
- Qichao Ni
View Affiliations

Affiliations: Department of Clinical Biobank, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: July 6, 2021 https://doi.org/10.3892/or.2021.8134
Article Number: 183

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erythropoietin‑producing hepatocellular receptors (Ephs) comprise the largest subfamily of receptor tyrosine kinases and have been reported to be involved in a variety of biological cellular processes, including tumorigenesis and cancer progression. The present study aimed to determine the expression levels and clinicopathological significance of EphA8 in breast cancer (BC) using immunohistochemistry analysis of tissue microarrays. The results of the present study revealed that EphA8 expression levels were upregulated in BC tissue and were associated with tumor size and TNM stage. In addition, upregulated expression levels of EphA8 were identified to be a poor prognostic biomarker for patients with BC. The knockdown of EphA8 expression using short hairpin RNA resulted in increased levels of apoptosis as well as decreased proliferation, migration and invasion of BC cells both in vivo and in vitro. The knockdown of EphA8 also decreased the phosphorylation of AKT, which was accompanied by downregulation of Bcl‑2 expression levels and upregulation of p53, Caspase‑3 and Bax expression levels. Moreover, knockdown of EphA8 expression increased the chemosensitivity of BC cells to paclitaxel. In conclusion, the results of the present study indicated that EphA8 may be a useful prognostic marker in BC and that knockdown of EphA8 may represent a novel strategy in adjuvant chemotherapy for the treatment of BC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Feb 4–2021.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
2	Januškevičienė I and Petrikaite V: Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. Life Sci. 239:1170092019. View Article : Google Scholar
3	Koren S and Bentires-Alj M: Breast tumor heterogeneity: Source of fitness, hurdle for therapy. Mol Cell. 60:537–546. 2015. View Article : Google Scholar : PubMed/NCBI
4	Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA and Burow ME: Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: Implications for breast cancer cell survival. Int J Oncol. 37:541–550. 2010.PubMed/NCBI
5	Lisabeth EM, Falivelli G and Pasquale EB: Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 5:a0091592013. View Article : Google Scholar : PubMed/NCBI
6	Boyd AW, Bartlett PF and Lackmann M: Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 13:39–62. 2014. View Article : Google Scholar : PubMed/NCBI
7	Nikolov DB, Xu K and Himanen JP: Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochim Biophys Acta. 1834:2160–2165. 2013. View Article : Google Scholar : PubMed/NCBI
8	Shiuan E and Chen J: Eph receptor tyrosine kinases in tumor immunity. Cancer Res. 76:6452–6457. 2016. View Article : Google Scholar : PubMed/NCBI
9	Pasquale EB: Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer. 10:165–180. 2010. View Article : Google Scholar : PubMed/NCBI
10	Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M and Vogt T: Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem. 50:490–499. 2004. View Article : Google Scholar : PubMed/NCBI
11	Nagano K, Maeda Y, Kanasaki S, Watanabe T, Yamashita T, Inoue M, Higashisaka K, Yoshioka Y, Abe Y, Mukai Y, et al: Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. J Control Release. 189:72–79. 2014. View Article : Google Scholar : PubMed/NCBI
12	Park S, Frisen J and Barbacid M: Aberrant axonal projections in mice lacking EphA8 (Eek) tyrosine protein kinase receptors. EMBO J. 16:3106–3114. 1997. View Article : Google Scholar : PubMed/NCBI
13	Kandouz M: The Eph/Ephrin family in cancer metastasis: Communication at the service of invasion. Cancer Metastasis Rev. 31:353–373. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gu C and Park S: The EphA8 receptor regulates integrin activity through p110gamma phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol Cell Biol. 21:4579–4597. 2001. View Article : Google Scholar : PubMed/NCBI
15	Kim Y, Park E, Noh H and Park S: Expression of EphA8-Fc in transgenic mouse embryos induces apoptosis of neural epithelial cells during brain development. Dev Neurobiol. 73:702–712. 2013. View Article : Google Scholar : PubMed/NCBI
16	Gu C, Shim S, Shin J, Kim J, Park J, Han K and Park S: The EphA8 receptor induces sustained MAP kinase activation to promote neurite outgrowth in neuronal cells. Oncogene. 24:4243–4256. 2005. View Article : Google Scholar : PubMed/NCBI
17	Liu X, Xu Y, Jin Q, Wang W, Zhang S, Wang X, Zhang Y, Xu X and Huang J: EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget. 7:20801–20809. 2016. View Article : Google Scholar : PubMed/NCBI
18	Murray S, Briasoulis E, Linardou H, Bafaloukos D and Papadimitriou C: Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 38:890–903. 2012. View Article : Google Scholar : PubMed/NCBI
19	Coradini D, Biganzoli E, Ardoino I, Ambrogi F, Boracchi P, Demicheli R, Daidone MG and Moliterni A: p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. Breast. 24:294–297. 2015. View Article : Google Scholar : PubMed/NCBI
20	Youngblood VM, Kim LC, Edwards DN, Hwang Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM and Chen J: The Ephrin-A1/EPHA2 signaling axis regulates glutamine metabolism in HER2-positive breast cancer. Cancer Res. 76:1825–1836. 2016. View Article : Google Scholar : PubMed/NCBI
21	Lodola A, Giorgio C, Incerti M, Zanotti I and Tognolini M: Targeting Eph/ephrin system in cancer therapy. Eur J Med Chem. 142:152–162. 2017. View Article : Google Scholar : PubMed/NCBI
22	Gu C and Park S: The p110 gamma PI-3 kinase is required for EphA8-stimulated cell migration. FEBS Lett. 540:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
23	Chen J, Song W and Amato K: Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev. 26:1–6. 2015. View Article : Google Scholar : PubMed/NCBI
24	Vaught D, Brantley-Sieders DM and Chen J: Eph receptors in breast cancer: Roles in tumor promotion and tumor suppression. Breast Cancer Res. 10:2172008. View Article : Google Scholar : PubMed/NCBI
25	Mathot L, Kundu S, Ljungstrom V, Svedlund J, Moens L, Adlerteg T, Falk-Sörqvist E, Rendo V, Bellomo C, Mayrhofer M, et al: Somatic ephrin receptor mutations are associated with metastasis in primary colorectal cancer. Cancer Res. 77:1730–1740. 2017. View Article : Google Scholar : PubMed/NCBI
26	Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C and Chen J: Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 70:299–308. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, et al: Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 169:279–293. 2006. View Article : Google Scholar : PubMed/NCBI
28	Noren NK, Foos G, Hauser CA and Pasquale EB: The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 8:815–825. 2006. View Article : Google Scholar : PubMed/NCBI
29	Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, His ED and Almasan A: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 6:e15932015. View Article : Google Scholar : PubMed/NCBI
30	Bernardi MP, Ngan SY, Michael M, Lynch AC, Heriot AG, Ramsay RG and Phillips WA: Molecular biology of anal squamous cell carcinoma: Implications for future research and clinical intervention. Lancet Oncol. 16:e611–e621. 2015. View Article : Google Scholar : PubMed/NCBI
31	Dey N, De P and Leyland-Jones B: PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Pharmacol Ther. 175:91–106. 2017. View Article : Google Scholar : PubMed/NCBI
32	Li JY, Xiao T, Yi HM, Yi H, Feng J, Zhu JF, Huang W, Lu SS, Zhou YH, Li XH and Xiao ZQ: S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties. Cancer Lett. 444:162–174. 2019. View Article : Google Scholar : PubMed/NCBI
33	Lucero M, Thind J, Sandoval J, Senaati S, Jimenez B and Kandpal RP: Stem-like cells from invasive breast carcinoma cell line MDA-MB-231 express a distinct set of Eph receptors and ephrin ligands. Cancer Genomics Proteomics. 17:729–738. 2020. View Article : Google Scholar : PubMed/NCBI
34	Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, et al: Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer. Clin Cancer Res. 24:2873–2885. 2018. View Article : Google Scholar : PubMed/NCBI
35	Lin YF, Tseng IJ, Kuo CJ, Lin HY, Chiu IJ and Chiu HW: High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy. J Cell Mol Med. 22:2458–2468. 2018. View Article : Google Scholar : PubMed/NCBI